FSD Pharma Inc.

CNSX: HUGE


Canadian symbol: HUGE.CN
US symbol: HUGE

Currency in CAD

Valuation Measures

Market Cap (intraday) 553M
Enterprise Value 335.36M
Trailing P/E N/A
Forward P/E 1N/A
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)206.15
Price/Book (mrq)0.80
Enterprise Value/Revenue 3137.52
Enterprise Value/EBITDA 6-0.99

Trading Information

Stock Price History

Beta (5Y Monthly) 0.49
52-Week Change 3-80.04%
S&P500 52-Week Change 310.60%
52 Week High 319.0955
52 Week Low 30.0000
50-Day Moving Average 33.8173
200-Day Moving Average 34.6555

Share Statistics

Avg Vol (3 month) 342.1k
Avg Vol (10 day) 39.01k
Shares Outstanding 514.72M
Float 10.22M
% Held by Insiders 113.19%
% Held by Institutions 10.00%
Shares Short (Aug. 13, 2020) 4190.94k
Short Ratio (Aug. 13, 2020) 42.64
Short % of Float (Aug. 13, 2020) 4N/A
Short % of Shares Outstanding (Aug. 13, 2020) 41.47%
Shares Short (prior month Jul. 14, 2020) 487.74k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 21:201
Last Split Date 3Oct. 15, 2019

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec. 30, 2019
Most Recent Quarter (mrq)Jun. 29, 2020

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-16,047.19%

Management Effectiveness

Return on Assets (ttm)-41.75%
Return on Equity (ttm)-93.65%

Income Statement

Revenue (ttm)257.1k
Revenue Per Share (ttm)0.03
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)-3.33M
EBITDA -35.61M
Net Income Avi to Common (ttm)-52.8M
Diluted EPS (ttm)-6.6560
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)13.39M
Total Cash Per Share (mrq)1.03
Total Debt (mrq)2.01M
Total Debt/Equity (mrq)4.38
Current Ratio (mrq)4.83
Book Value Per Share (mrq)4.48

Cash Flow Statement

Operating Cash Flow (ttm)-19.11M
Levered Free Cash Flow (ttm)-17.15M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Cannabis Market and Business News

Real-time cannabis business news from hundreds of sources. Never miss the news that matters the most.




Company News Date
HUGE.CN
FSD Pharma
2 weeks ago
HUGE.CN
FSD Pharma
1 month ago
HUGE.CN
FSD Pharma
1 month ago
HUGE.CN
FSD Pharma
1 month ago
HUGE.CN
FSD Pharma
1 month ago
HUGE.CN
FSD Pharma
1 month ago
HUGE.CN
FSD Pharma
1 month ago
HUGE.CN
FSD Pharma
3 months ago
HUGE.CN
FSD Pharma
3 months ago
HUGE.CN
FSD Pharma
3 months ago
HUGE.CN
FSD Pharma
3 months ago
HUGE.CN
FSD Pharma
3 months ago
HUGE.CN
FSD Pharma
6 months ago
HUGE.CN
FSD Pharma
6 months ago
HUGE.CN
FSD Pharma
6 months ago
HUGE.CN
FSD Pharma
6 months ago
HUGE.CN
FSD Pharma
7 months ago
HUGE.CN
FSD Pharma
8 months ago
HUGE.CN
FSD Pharma
8 months ago
HUGE.CN
FSD Pharma
8 months ago
HUGE.CN
FSD Pharma
8 months ago
HUGE.CN
FSD Pharma
8 months ago
HUGE.CN
FSD Pharma
9 months ago
HUGE.CN
FSD Pharma
9 months ago
HUGE.CN
FSD Pharma
9 months ago
HUGE.CN
FSD Pharma
9 months ago
HUGE.CN
FSD Pharma
9 months ago
HUGE.CN
FSD Pharma
9 months ago
HUGE.CN
FSD Pharma
9 months ago
HUGE.CN
FSD Pharma
9 months ago
HUGE.CN
FSD Pharma
9 months ago
HUGE.CN
FSD Pharma
9 months ago
HUGE.CN
FSD Pharma
10 months ago
HUGE.CN
FSD Pharma
10 months ago
HUGE.CN
FSD Pharma
10 months ago
HUGE.CN
FSD Pharma
11 months ago
HUGE.CN
FSD Pharma
11 months ago
HUGE.CN
FSD Pharma
11 months ago
HUGE.CN
FSD Pharma
11 months ago
HUGE.CN
FSD Pharma
11 months ago
HUGE.CN
FSD Pharma
11 months ago
HUGE.CN
FSD Pharma
12 months ago
HUGE.CN
FSD Pharma
12 months ago
HUGE.CN
FSD Pharma
12 months ago
HUGE.CN
FSD Pharma
12 months ago
HUGE.CN
FSD Pharma
1 year ago
HUGE.CN
FSD Pharma
1 year ago
HUGE.CN
FSD Pharma
1 year ago
HUGE.CN
FSD Pharma
1 year ago
HUGE.CN
FSD Pharma
1 year ago
HUGE.CN
FSD Pharma
1 year ago
HUGE.CN
FSD Pharma
1 year ago
HUGE.CN
FSD Pharma
1 year ago
HUGE.CN
FSD Pharma
1 year ago
HUGE.CN
FSD Pharma
1 year ago
HUGE.CN
FSD Pharma
1 year ago
HUGE.CN
FSD Pharma
1 year ago
HUGE.CN
FSD Pharma
1 year ago
HUGE.CN
FSD Pharma
1 year ago
HUGE.CN
FSD Pharma
1 year ago
HUGE.CN
FSD Pharma
1 year ago
HUGE.CN
FSD Pharma
1 year ago
HUGE.CN
FSD Pharma
1 year ago
HUGE.CN
FSD Pharma
1 year ago
HUGE.CN
FSD Pharma
1 year ago
HUGE.CN
FSD Pharma
1 year ago
HUGE.CN
FSD Pharma
1 year ago
HUGE.CN
FSD Pharma
1 year ago
HUGE.CN
FSD Pharma
1 year ago
HUGE.CN
FSD Pharma
1 year ago
HUGE.CN
FSD Pharma
1 year ago
HUGE.CN
FSD Pharma
1 year ago
HUGE.CN
FSD Pharma
1 year ago
HUGE.CN
FSD Pharma
1 year ago
HUGE.CN
FSD Pharma
1 year ago
HUGE.CN
FSD Pharma
1 year ago

Analysts data is not available


Insiders transactions are updated every hour.

Major Holders

Currency in CAD
Breakdown
13.19%% of Shares Held by All Insider
0.00%% of Shares Held by Institutions
0.00%% of Float Held by Institutions
2Number of Institutions Holding Shares
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by FSD Pharma Inc.


FSD Pharma Announces Phase 2 Clinical Trial IND Filing With The FDA to Treat Patients With COVID-19

FSD Pharma Announces Phase 2 Clinical Trial IND Filing With The FDA to Treat Patients With COVID-19

TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (“FSD Pharma” or the “Company”) today announced that it has submitted to the U.S. Food and Drug Administration (“FDA”) an Investigational New Drug Application (IND) for the use of FSD201 (ultramicronized palmitoylethanolamide, or ultramicronized PEA) to treat COVID-19... Read More...
FSD Pharma Inc. Announces Closing of US$10 Million Registered Direct Offering to Institutional Investors

FSD Pharma Inc. Announces Closing of US$10 Million Registered Direct Offering to Institutional Investors

FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) ("FSD Pharma") announces the closing of a previously announced agreement with investors for the purchase and sale of 2,762,430 Class B Subordinate Voting Shares of the Company ("Shares") and warrants to purchase 1,381,215 Shares (collectively, the "Securities") at a purchase price of US$3.62 p... Read More...
FSD Pharma Announces Decision to Surrender Health Canada Licenses for Subsidiary FV Pharma Inc.

FSD Pharma Announces Decision to Surrender Health Canada Licenses for Subsidiary FV Pharma Inc.

- FV Pharma to shut down operations within 30 days -FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) ("FSD Pharma" or the "Company") today announced that it has notified Health Canada of the Company’s decision to forfeit the licenses of its wholly-owned subsidiary, FV Pharma, Inc. ("FV Pharma") and suspend all activities by FV Ph... Read More...
FSD Pharma Announces US$20M At-The-Market Offering

FSD Pharma Announces US$20M At-The-Market Offering

TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (“FSD Pharma” or the “Company”) today announced that it has entered into an Equity Distribution Agreement dated July 10, 2020 (the “Sales Agreement”) with A.G.P./Alliance Global Partners (the “Sales Agent”). Under the Sales Agreement the Company may, at its discretion... Read More...
FSD Pharma Reports Favorable Topline Results from Phase 1 First-in-Human Safety and Tolerability Study of Ultramicronized PEA

FSD Pharma Reports Favorable Topline Results from Phase 1 First-in-Human Safety and Tolerability Study of Ultramicronized PEA

All subjects completed the trial per protocol, no safety concerns found up to the highest dose tested of 2400 mg/dayFSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) ("FSD Pharma") today announced favorable topline results from its Phase 1 randomized, double-blind, placebo-controlled study of ultramicronized palmitoylethanolamide ... Read More...
FSD Pharma Announces Closing of C$10.125 Million Private Placement to Institutional Investors

FSD Pharma Announces Closing of C$10.125 Million Private Placement to Institutional Investors

TORONTO, June 9, 2020 - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (the "Company") announces the closing of a previously announced private placement of 1,500,000 of the Company's Class B Subordinate Voting Shares ("Shares") at a price of C$6.75 per Share and warrants to purchase 1,500,000 Shares (cumulatively, the "Securiti... Read More...
FSD Pharma Receives U.S. FDA Approval to design a Phase 2a Clinical Trial to Treat Patients with Suspected or Confirmed COVID-19 Diagnosis

FSD Pharma Receives U.S. FDA Approval to design a Phase 2a Clinical Trial to Treat Patients with Suspected or Confirmed COVID-19 Diagnosis

TORONTO , June 3, 2020 - FSD Pharma Inc. (HUGE.CN) (HUGE.CN) (0K9A.F) ("FSD Pharma") today announced that the U.S. Food and Drug Administration (FDA) has given the company permission to submit an Investigational New Drug Application (IND) for the use of FSD-201 (ultramicronized palmitoylethanolamide, or ultramicronized PEA) to treat COVID... Read More...
FSD Pharma Monetizes Non-Core Asset with Sale of Partial Equity Stake in Pharmadrug Inc.

FSD Pharma Monetizes Non-Core Asset with Sale of Partial Equity Stake in Pharmadrug Inc.

- Buyer Holds Option to Purchase Additional Shares - TORONTO, May 21, 2020 - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) ("FSD Pharma" or the "Company") today announced the sale of 5.0 million common shares of Pharmadrug Inc. (CSE: BUZZ) (formerly Aura Health) in a privately negotiated transaction at C$0.08 per share for ca... Read More...
FSD Pharma Takes Steps to Mitigate the Impact of COVID-19 on its Cannabis Production Facility in Cobourg, Ontario

FSD Pharma Takes Steps to Mitigate the Impact of COVID-19 on its Cannabis Production Facility in Cobourg, Ontario

TORONTO, March 23, 2020 - FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) ("FSD Pharma" or the "Company") today announced that it has taken steps to mitigate the impact of the novel coronavirus SARS-CoV-2 pandemic on its wholly-owned subsidiary, FV Pharma Inc. ("FV Pharma"), a licensed producer under Canada's Cannabis Act and Re... Read More...
FSD Pharma Begins Phase 1 In-human Safety and Tolerability Study of Ultra Micro-Palmitolylethanolamide (PEA)

FSD Pharma Begins Phase 1 In-human Safety and Tolerability Study of Ultra Micro-Palmitolylethanolamide (PEA)

TORONTO, March 9, 2020 - FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company") today announced receipt of approval from the Ethics Committee of the Alfred Hospital, part of the Alfred Health group of hospitals serving the state of Victoria in Australia, to initiate a Phase 1, randomized, double-blind, plac... Read More...
FSD Pharma to Ring the Opening Bell of the Canadian Securities Exchange On Friday, March 6, 2020

FSD Pharma to Ring the Opening Bell of the Canadian Securities Exchange On Friday, March 6, 2020

TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma”) today announced that Executive Co-Chairman and CEO, Raza Bokhari, MD will be joined by the Company’s founders, Anthony Durkacz and Zeeshan Saeed, members of its Board of Directors, and leadership team to ring the opening bell at the Canadian Se... Read More...
FSD Pharma Generates $7.7 Million in Proceeds and 670% Return on Investment through Sale of Interest in Cannara Biotech

FSD Pharma Generates $7.7 Million in Proceeds and 670% Return on Investment through Sale of Interest in Cannara Biotech

TORONTO, Feb. 20, 2020 - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company") today announced the sale of its 12% equity interest in Cannara Biotech Inc. (CSE: LOVE) ("Cannara") to a consortium of buyers for cash proceeds of more than $7.7 million (the "Share Sale Transaction"). The terms of the Share Sal... Read More...
Integrated Cannabis Announces Amendment to Share Exchange Agreement with 1200665 B.C. Ltd.

Integrated Cannabis Announces Amendment to Share Exchange Agreement with 1200665 B.C. Ltd.

Integrated Cannabis Settles an Aggregate of $12,500,000 in Outstanding DebtVANCOUVER, British Columbia, Feb. 11, 2020 -- Integrated Cannabis Company, Inc. (CSE: ICAN, OTCQB: ICNAF) (“Integrated Cannabis” or the “Company”), a multi-state brand operator in California and Nevada, is pleased to announce that it has entered into an amending ag... Read More...
Seasoned Healthcare Executive and Academic Luminary Larry Kaiser, MD, Joins FSD Pharma Board of Directors

Seasoned Healthcare Executive and Academic Luminary Larry Kaiser, MD, Joins FSD Pharma Board of Directors

TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma”) today announced that it has appointed Larry Kaiser, MD, FACS to its Board of Directors, effective immediately. Dr. Kaiser will also continue to serve as the Chairman of FSD Pharma’s Scientific Advisory Board (SAB). Dr. Kaiser is currently th... Read More...
FSD Pharma to Ring Nasdaq Opening Bell on Wednesday, January 22, 2020

FSD Pharma to Ring Nasdaq Opening Bell on Wednesday, January 22, 2020

TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma”) is pleased to announce that Executive Co-Chairman and CEO Dr. Raza Bokhari, along with the founders, members of the Company’s Board of Directors, members of the leadership team, early investors, advisors, and other stakeholders, will ring the Na... Read More...
INSERTING and REPLACING FSD Pharma to Commence Trading on Nasdaq Capital Market Under Symbol ‘HUGE'

INSERTING and REPLACING FSD Pharma to Commence Trading on Nasdaq Capital Market Under Symbol ‘HUGE’

TORONTO--(BUSINESS WIRE)--Insert in second paragraph, first sentence of release: Executive Co-Chairman and CEO. The corrected release reads: FSD PHARMA TO COMMENCE TRADING ON NASDAQ CAPITAL MARKET UNDER SYMBOL ‘HUGE’ - Management to Present at Biotech Showcase 2020 - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Ph... Read More...
FSD Pharma to Commence Trading on Nasdaq Capital Market Under Symbol ‘HUGE'

FSD Pharma to Commence Trading on Nasdaq Capital Market Under Symbol ‘HUGE’

TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma”) announced that its Class B Subordinate Voting Shares (the “Shares”) will commence trading on the Nasdaq Capital Market under the symbol ‘HUGE’ today, January 9, 2020. The Company’s Class B Subordinate Voting Shares will continue to trade on the ... Read More...
FSD Pharma to Begin Trading on the NASDAQ Capital Market Under Symbol 'HUGE' on January 9, 2020

FSD Pharma to Begin Trading on the NASDAQ Capital Market Under Symbol ‘HUGE’ on January 9, 2020

TORONTO , Jan. 6, 2020 - FSD Pharma Inc. (HUGE.CN) (FSDDF) (0K9.F) ("FSD Pharma") today announced that its Class B Subordinate Voting Shares (the "Shares") have been approved for listing on the NASDAQ Capital Market ("NASDAQ") under the symbol 'HUGE'. Trading on the NASDAQ is expected to commence at market open on Thursday, January 9, 202... Read More...
FSD Pharma to Begin Trading on the NASDAQ Capital Market Under Symbol ‘HUGE' on January 9, 2020

FSD Pharma to Begin Trading on the NASDAQ Capital Market Under Symbol ‘HUGE’ on January 9, 2020

TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD Pharma”) today announced that its Class B Subordinate Voting Shares (the “Shares”) have been approved for listing on the NASDAQ Capital Market (“NASDAQ”) under the symbol ‘HUGE’. Trading on the NASDAQ is expected to commence at market open on Thursday, J... Read More...
FSD Pharma Strengthens Management Team

FSD Pharma Strengthens Management Team

- Donal Carroll Appointed Chief Financial Officer, Dr. Sandra Lottes as Vice President and Head of Clinical Research at BioSciences Division, and Shahzad Shah as Chief Operating Officer at FV Pharma - TORONTO, Jan. 2, 2020 - FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD Pharma") today announced the appointments of three key... Read More...
FSD Pharma to Present at 12th Annual LD Micro Main Event Investor Conference on December 11

FSD Pharma to Present at 12th Annual LD Micro Main Event Investor Conference on December 11

TORONTO, Dec. 5, 2019 - FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD Pharma") announces that Edward Brennan, MD, President, BioSciences Division, will present an overview of the Company at the 12th Annual LD Micro Main Event Investor conference at 12:20 p.m. PT/3:20 p.m. ET on Wednesday, December 11, 2019 at the Luxe Sunset... Read More...
Integrated Cannabis Shareholders Agree to a Voluntary Six-Month Hold

Integrated Cannabis Shareholders Agree to a Voluntary Six-Month Hold

Approximately 26 Million Shares Will Be Restricted Until May 1st, 2020VANCOUVER, British Columbia, Nov. 05, 2019 -- Integrated Cannabis Company, Inc. (CSE: ICAN, OTCQB: ICNAF) (“Integrated Cannabis” or the “Company”), is pleased to announce it, together with certain shareholders of the Company have entered into a voluntary pooling agreeme... Read More...
FSD Pharma Second Tranche of Private Placement Closes, Total of $4.59 Million Raised at $20.10 To Date, Extends Offering

FSD Pharma Second Tranche of Private Placement Closes, Total of $4.59 Million Raised at $20.10 To Date, Extends Offering

/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES./ TORONTO, Nov. 4, 2019 - FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDD) (FRA: 0K9) ("FSD") announces that it has closed a second tranche of its previously announced ... Read More...
FSD Pharma Appoints Former Member of U.S. Congress to its Board of Directors, Announces Share Consolidation

FSD Pharma Appoints Former Member of U.S. Congress to its Board of Directors, Announces Share Consolidation

TORONTO, Oct. 11, 2019 - FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD") today announced the appointment of former U.S. congressman Stephen Buyer to the Company's Board of Directors. The Company also announced that it will complete a consolidation of its class A multiple voting shares ("Class A Shares") and its class B subor... Read More...
Integrated Cannabis' Ganja Gold Announces California Launch of first CBD Infused Pre-Roll

Integrated Cannabis’ Ganja Gold Announces California Launch of first CBD Infused Pre-Roll

VANCOUVER, British Columbia, Oct. 08, 2019 -- Integrated Cannabis Company, Inc. (CSE: ICAN, OTCQB: ICNAF) (“Integrated Cannabis” or the “Company”), a multi-state brand operator in California and Nevada, is pleased to announce that its wholly-owned subsidiary, Ganja Gold, has launched the first cannabidiol (CBD) infused pre-roll in Califor... Read More...
FSD Pharma Closes First Tranche of Private Placement at $4.58 Million, Extends Offering

FSD Pharma Closes First Tranche of Private Placement at $4.58 Million, Extends Offering

TORONTO, Oct. 1, 2019 - FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD" or the "Company") is pleased to provide an update on its previously announced private placement of its class B subordinate voting shares ("Shares") at a price of CAD$0.10 per Share (the "Private Placement").  On September 30, 2019, the Company c... Read More...
Integrated Cannabis' Ganja Gold takes Delivery of Fully Automated Proprietary Pre-Roll Manufacturing Machine

Integrated Cannabis’ Ganja Gold takes Delivery of Fully Automated Proprietary Pre-Roll Manufacturing Machine

VANCOUVER, British Columbia, Oct. 01, 2019 -- Integrated Cannabis Company, Inc. (CSE: ICAN, OTCQB: ICNAF) (“Integrated Cannabis” or the “Company”), a multi-state brand operator in California and Nevada, is pleased to announce that its wholly-owned subsidiary, Ganja Gold, has taken delivery of a first generation, custom built, fully automa... Read More...
FSD Pharma Signs LOI to Establish Joint Venture with World-Class Extractions to Deploy Full Extraction Processing Center

FSD Pharma Signs LOI to Establish Joint Venture with World-Class Extractions to Deploy Full Extraction Processing Center

-  Joint Venture to develop, manage and operate cannabis extraction and processing center at FSD Pharma Facility in Cobourg, Ontario - TORONTO, Sept. 25, 2019 - FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) ("FSD Pharma", "FSD" or "the Company") today announced the signing of a letter of inten... Read More...
Coming Soon.

Delayed data (1h)
NameAgePositionAppointed
Raza Bokhari
Executive Co-Chairman of the Board, Chief Executive Officer
50Executive Co-Chairman of the Board, Chief Executive Officer2019
Anthony Durkacz
Executive Co-Chairman of the Board
39Executive Co-Chairman of the Board2018
Zeeshan Saeed
President, Director
--President, Director2018
Donal Carroll
Chief Financial Officer
--Chief Financial Officer2020
Sandra Lottes
Vice President & Head of Clinical Research of FSD Pharma's BioSciences Division
--Vice President & Head of Clinical Research of FSD Pharma's BioSciences Division2020
Shahzad Shah
Chief Operating Officer of FV Pharma
--Chief Operating Officer of FV Pharma2020
Larry R. Kaiser
Director
--Director2020
Stephen Buyer
Independent Director
--Independent Director2019
Robert J. Ciaruffoli
Independent Director
--Independent Director2019
James Anthony Datin
Independent Director
54Independent Director2019
Gerald Goldberg
Independent Director
--Independent Director2018
David A. Urban
Independent Director
56Independent Director2018


Share this page